Search by Drug Name or NDC
NDC 00187-4100-10 Librax 5; 2.5 mg/1; mg/1 Details
Librax 5; 2.5 mg/1; mg/1
Librax is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bausch Health US, LLC. The primary component is CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE.
MedlinePlus Drug Summary
The combination of chlordiazepoxide and clidinium is used along with other medications to treat peptic ulcers, irritable bowel syndrome (IBS; a condition that causes stomach pain, bloating, constipation, and diarrhea), and enterocolitis (swelling in the intestines). Chlordiazepoxide is in a class of medications called benzodiazepines. It works by decreasing abnormal electrical activity in the brain. Clidinium is in a class of medications called anticholinergics. It helps to decrease stomach spasms and cramps.
Related Packages: 00187-4100-10Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Chlordiazepoxide and Clidinium
Product Information
| NDC | 00187-4100 |
|---|---|
| Product ID | 0187-4100_98fd8b52-2fc3-4540-8333-75b5c853aee2 |
| Associated GPIs | 49109902450110 |
| GCN Sequence Number | 004902 |
| GCN Sequence Number Description | chlordiazepoxide/clidinium Br CAPSULE 5 MG-2.5MG ORAL |
| HIC3 | J2B |
| HIC3 Description | ANTICHOLINERGICS,QUATERNARY AMMONIUM |
| GCN | 74801 |
| HICL Sequence Number | 002037 |
| HICL Sequence Number Description | CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE |
| Brand/Generic | Brand |
| Proprietary Name | Librax |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Chlordiazepoxide Hydrochloride and Clidinium Bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 5; 2.5 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Labeler Name | Bausch Health US, LLC |
| Pharmaceutical Class | Anticholinergic [EPC], Benzodiazepine [EPC], Benzodiazepines [CS], Cholinergic Antagonists [MoA], Decreased Parasympathetic Acetylcholine Activity [PE], Digestive/GI System Activity Alteration [PE], GI Motility Alteration [PE] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA012750 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00187-4100-10 (00187410010)
| NDC Package Code | 0187-4100-10 |
|---|---|
| Billing NDC | 00187410010 |
| Package | 100 CAPSULE in 1 BOTTLE (0187-4100-10) |
| Marketing Start Date | 1966-09-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |